News


All series


All News

Treatment with durvalumab demonstrated objective responses in approximately one-fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.

Advances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br /> &nbsp;

At practices with their own pharmacies, many patients are now given the option of picking up prescriptions directly from the clinic, known as medically integrated dispensing. Proponents of this method believe that it provides for better patient outcomes, allows for better tracking of patient adherence, and is substantially more cost effective.&nbsp;

A supplemental biologics license application submitted to the FDA for&nbsp;atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the&nbsp;phase III IMpower130 trial, is seeking the agent&#39;s approval for&nbsp;patients with metastatic nonsquamous non&ndash;small cell lung cancer.

The&nbsp;investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA&nbsp;for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy,&nbsp;BeiGene, the company manufacturing the agent, has announced.

ASLAN Pharmaceuticals, the company developing varlitinib (ASLAN001), has announced that a phase II frontline trial investigating the&nbsp;pan-HER inhibitor added to mFOLFOX6 in patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer has missed its primary endpoint.